Companies Pfizer

Pfizer

Chennai

Total Offices: 2

121,990 Total Employees

Year Founded: 1848

View Website

We're Hiring!

Healthcare Services 1

View all jobs

Pfizer Innovation & Technology Culture

Pfizer Employee Perspectives

It’s a multi-disciplinary approach that allows us to integrate cutting-edge technologies like AI and machine learning into our research processes, enabling us to make faster and bigger strides in understanding and treating cancer.

Mack MacKenzie, VP of Digital for Oncology, Business Innovation and Enterprise AI

From the article: Pfizer Leadership: How The Company is Redefining the World’s Approach to Cancer Research

What People Are Saying About Pfizer

Product Innovation: Feedback suggests Pfizer repeatedly converts new science into approved products at scale, including the first widely used mRNA COVID-19 vaccine, full approval of Paxlovid, multi-population RSV approvals (Abrysvo), oncology assets (e.g., Tivdak/Elrexfio), and a hemophilia B gene therapy. A diversified late-stage slate—especially in ADCs and immuno-oncology—indicates strong near-term conversion potential.
Process Innovation: Feedback suggests parallel workstreams, rapid clinical execution, and industrial scale-up enabled an mRNA vaccine from concept to authorization in under a year, while continuous manufacturing and advanced analytics shortened key production steps. Formal AI collaborations and a global digital innovation center further aim to compress R&D and supply chain cycle times.
Emerging Technology Adoption: Feedback suggests Pfizer has leaned into frontier modalities—mRNA platforms, ADCs via the Seagen acquisition, gene therapy—and enterprise AI to broaden its innovation toolkit. These bets expand modality diversity in oncology and vaccines and position programs for multi-indication growth.